Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform, Verisome®.
IBI's Verisome® drug delivery technology is the most advanced, yet simplest system for controlling the release of intraocular therapeutic agents in the eye for extended periods of time. Its unmatched versatility can support products individually formulated to meet the specific clinical requirements of a given active agent targeting a specific ophthalmic disease.
IBI's current portfolio consists of seven (7) proprietary products, all targeting significant unmet ophthalmic medical needs. These include two (2) products at the clinical stage of development with two (2) more scheduled to begin human trials in 2013. Over 200 patients have been administered products based on the Verisome® drug delivery technology. IBI has also executed research agreements with multiple global pharmaceutical companies.
IBI-10090 will be Icon’s first product developed using the Verisome® technology to reach the market. IBI-10090 is a biodegradable product for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.
IBI-10090 is intended to be injected into the anterior chamber of the eye immediately after cataract surgery and safely deliver therapeutic levels of the active ingredient, dexamethasone. It is designed to eliminate the need for … Read more
Icon Bioscience, Inc. will pursue corporate partnerships and out-licensing agreements of its Verisome® technology in limited opportunistic circumstances. IBI is currently involved with multiple collaborations involving a wide variety of new chemical entities targeting various ophthalmic indications. These collaborations involve small molecules and biologics … Read More
David S. Tierney, M.D.
Chief Executive Officer
1253 Reamwood Avenue
Sunnyvale, California 94089
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049